GlassScriptPhysician profile
William David Hoover
NPI 1134539638
$51,965.52
in general payments reported to CMS, 2019-2025
34 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $75.48 · 2021: $306 · 2022: $9,336 · 2023: $6,908 · 2024: $16K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $1,253 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,502.50 |
| Food and Beverage | $11,176.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,413.00 |
| Travel and Lodging | $1,253.43 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,764.81 | 2019-2025 | |
| Janssen Biotech, INC. | $10,098.00 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $7,340.81 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $1,800.31 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,075.53 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,057.12 | 2019-2025 | Ilumya |
| Genzyme Corporation | $1,003.34 | 2021-2025 | |
| Pfizer INC. | $884.75 | 2023-2025 | |
| Ucb, INC. | $796.38 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $687.20 | 2019-2025 | |
| Galderma Laboratories, L.P. | $448.10 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Dermavant Sciences, INC. | $401.80 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $400.68 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $302.14 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $274.30 | 2024-2025 | Otezla, Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $263.81 | 2023-2025 | Zoryve |
| Almirall LLC | $234.74 | 2021-2024 | Klisyri |
| Journey Medical Corporation | $221.68 | 2022-2024 | |
| Medimetriks Pharmaceuticals, INC. | $189.21 | 2021-2024 | Neuac |
| Organon LLC | $131.43 | 2025 | Vtama |
| Convatec INC. | $75.79 | 2025 | |
| Botanix Sb INC | $69.95 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.45 | 2019 | |
| Janssen Scientific Affairs, LLC | $62.54 | 2025 | Tremfya |
| Mayne Pharma Commercial LLC | $55.37 | 2024 | |
| Biofrontera INC. | $51.15 | 2020-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Celgene Corporation | $46.62 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $36.99 | 2025 | Dupixent |
| Kyowa Kirin, INC. | $31.76 | 2023-2024 | Poteligeo |
| Cipher Pharmaceuticals US LLC | $21.50 | 2025 | Spinosad, Natroba |
| Merz North America, INC. | $21.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.22 | 2024 | Spevigo |
| Lnhc, INC | $15.52 | 2025 | Zelsuvmi |
| Dusa Pharmaceuticals, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hoover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.